BusinessAchillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D InhibitorBy Nasdaq OMXAug 8, 2017, 8:02 PM UTC
BusinessAchillion to Present at the 2017 JMP Securities Life Sciences ConferenceBy Nasdaq OMXJun 15, 2017, 8:05 PM UTC
BusinessAchillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical ProgramsBy Nasdaq OMXMay 4, 2017, 10:05 AM UTC
BusinessAchillion to Present at the Deutsche Bank 42nd Annual Health Care ConferenceBy Nasdaq OMXMay 2, 2017, 10:05 AM UTC
BusinessAchillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal HemoglobinuriaBy Nasdaq OMXApr 6, 2017, 10:05 AM UTC
BusinessUSPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D InhibitorsBy Nasdaq OMXMar 21, 2017, 8:05 PM UTC
BusinessData Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated DiseasesBy Nasdaq OMXDec 5, 2016, 9:05 PM UTC
BusinessAchillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of HematologyBy Nasdaq OMXNov 3, 2016, 1:01 PM UTC
